A Phase 2 interventional study of Cenerimod 0.5 mg and Cenerimod 1 mg in Systemic Lupus Erythematosus, sponsored by Viatris Innovation GmbH. Completed at 148 sites in 24 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 48th largest by enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2018, is one of 120 in phase 2, and was the 278th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 29 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 427 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
This study is registered under Viatris Innovation GmbH, one of the names counted as Viatris Inc.. Under that name alone:
Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Viatris Inc. has 7 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently treated with stable doses of one or more of the following background medications:
Women of :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cenerimod 0.5 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 0.5 mg for a further 6 months and end study treatment at the Month 12 visit.
Drug: Cenerimod 0.5 mg
Participants will receive cenerimod 1 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 1 mg for a further 6 months and end study treatment at the Month 12 visit.
Drug: Cenerimod 1 mg
Participants will receive cenerimod 2 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 2 mg for a further 6 months and end study treatment at the Month 12 visit.
Drug: Cenerimod 2 mg
Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to cenerimod 2 mg once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.
Drug: cenerimod 2 mg (ex-4 mg)
Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to placebo (matching cenerimod) once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.
Drug: Placebo
Participants will received cenerimod 4 mg once daily in addition to background SLE therapy for up to 6 months in Treatment Period 1. The participants randomized to the 4 mg treatment who were still on treatment at Month 6 were re-randomized in a 1:1 ratio to placebo or cenerimod 2 mg to enter Treatment Period 2. The participants who did not complete 6 months of cenerimod 4 mg treatment will be analyzed in the "Non Re-randomized (Ex-4mg)" treatment group.
Drug: Cenerimod 4 mg
Participants will receive placebo (matching cenerimod) once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with placebo (matching cenerimod) for a further 6 months and end study treatment at the Month 12 visit.
Drug: Placebo
Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score
The primary endpoint is the absolute change from baseline in the modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) score. The SLEDAI-2K is a cumulative index of lupus disease activity scored by the physician. It is calculated from 24 individual descriptors across 9 organ systems, with weighted scores of 2-8, and measures disease activity within the last 10 days. 0 points indicates inactive disease, and 105 points is the maximum possible score. In this study the SLEDAI-2K was modified, to exclude leucopenia (minus 1 point), due to the mechanism of action of cenerimod. Improvement in systemic lupus erythematosus disease activity is defined as a reduction in SLEDAI-2K score of greater than or equal to 4. A decreased score, i.e., a negative change, indicates an improvement in systemic lupus erythematosus disease activity from baseline to Month 6.
Time frame: Baseline (Day 1) and Month 6
Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 6 as Compared to Baseline
A responder could only be assessed if the full information of all body systems was available. A participant was defined as a responder based on the Systemic Lupus Erythematosus Responder Index 4 (SRI-4) was a composite, binary endpoint based on three variables: * mSLEDAI-2K score had to have a reduction from baseline greater than or equal to 4, * Physician Global Assessment (PGA) had to have an increase from baseline less than or equal to 0.3. The PGA is a 100 mm visual analog scale used by the physician to assess disease activity ranging for 0 to 3. The scale is anchored with values from 0 = "none" and 3 = "severe"), and * BILAG-2004 (no new BILAG A organ domain score and at most one new BILAG B organ domain score) compared with baseline. If one of the SRI-4 mSLEDAI-2K, PGA and BILAG variables were not met the subject was scored a non-responder. Participants that did not fit at least one of the above criteria were assigned to the missing group.
Time frame: Baseline (Day 1) and Month 6
British Isles Lupus Assessment Group-2004 (BILAG) Disease Activity Index Response at Month 6
The British Isles Lupus Assessment Group-2004 (BILAG) is a comprehensive tool used by the physician to assess disease activity and is sensitive to small changes over time. Response (no worsening) at Month 6 on BILAG-2004 disease activity index was defined as no new BILAG A organ domain score and no more than one new BILAG B organ domain score compared with baseline. No analysis is reported because the model did not meet the convergence criteria.
Time frame: Baseline (Day 1) and Month 6
The study was done from 21 December 2018 to 25 August 2022.
| Milestone | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 2 mg (Ex-4 mg) | Placebo (Ex-4 mg) | Cenerimod 4 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 85 | 85 | 86 | 0 | 0 | 85 | 86 |
| Completed | 78 | 78 | 71 | 0 | 0 | 70 | 77 |
| Not completed | 7 | 7 | 15 | 0 | 0 | 15 | 9 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 4 | 0 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 | 2 | 0 | 0 | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pre-specified criteria | 1 | 3 | 7 | 0 | 0 | 6 | 1 |
| Withdrew: Randomized but no study treatment taken | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other reasons | 2 | 0 | 2 | 0 | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 2 mg (Ex-4 mg) | Placebo (Ex-4 mg) | Cenerimod 4 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 78 | 78 | 72 | 35 | 35 | 0 | 77 |
| Completed | 74 | 74 | 59 | 30 | 35 | 0 | 68 |
| Not completed | 4 | 4 | 13 | 5 | 0 | 0 | 9 |
| Withdrew: Adverse event | 1 | 2 | 3 | 1 | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 2 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Pre-specified criteria | 0 | 1 | 3 | 2 | 0 | 0 | 2 |
| Withdrew: Other reasons | 2 | 0 | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Discontinued study treatment in treatment period 1, re-randomized in error | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The primary endpoint is the absolute change from baseline in the modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) score. The SLEDAI-2K is a cumulative index of lupus disease activity scored by the physician. It is calculated from 24 individual descriptors across 9 organ systems, with weighted scores of 2-8, and measures disease activity within the last 10 days. 0 points indicates inactive disease, and 105 points is the maximum possible score. In this study the SLEDAI-2K was modified, to exclude leucopenia (minus 1 point), due to the mechanism of action of cenerimod. Improvement in systemic lupus erythematosus disease activity is defined as a reduction in SLEDAI-2K score of greater than or equal to 4. A decreased score, i.e., a negative change, indicates an improvement in systemic lupus erythematosus disease activity from baseline to Month 6.
| score on a scale | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score | -3.2 (-3.98 to -2.49) | -3.41 (-4.16 to -2.67) | -2.84 (-3.58 to -2.09) | -4.04 (-4.79 to -3.28) | -2.85 (-3.60 to -2.10) |
A responder could only be assessed if the full information of all body systems was available. A participant was defined as a responder based on the Systemic Lupus Erythematosus Responder Index 4 (SRI-4) was a composite, binary endpoint based on three variables: * mSLEDAI-2K score had to have a reduction from baseline greater than or equal to 4, * Physician Global Assessment (PGA) had to have an increase from baseline less than or equal to 0.3. The PGA is a 100 mm visual analog scale used by the physician to assess disease activity ranging for 0 to 3. The scale is anchored with values from 0 = "none" and 3 = "severe"), and * BILAG-2004 (no new BILAG A organ domain score and at most one new BILAG B organ domain score) compared with baseline. If one of the SRI-4 mSLEDAI-2K, PGA and BILAG variables were not met the subject was scored a non-responder. Participants that did not fit at least one of the above criteria were assigned to the missing group.
| participants | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo |
|---|---|---|---|---|---|
| Responder | 36 | 41 | 38 | 41 | 34 |
| Non-responder | 45 | 38 | 41 | 36 | 43 |
| Missing | 4 | 6 | 7 | 8 | 9 |
The British Isles Lupus Assessment Group-2004 (BILAG) is a comprehensive tool used by the physician to assess disease activity and is sensitive to small changes over time. Response (no worsening) at Month 6 on BILAG-2004 disease activity index was defined as no new BILAG A organ domain score and no more than one new BILAG B organ domain score compared with baseline. No analysis is reported because the model did not meet the convergence criteria.
| percentage of participants | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo |
|---|---|---|---|---|---|
| British Isles Lupus Assessment Group-2004 (BILAG) Disease Activity Index Response at Month 6 | 98.8 | 98.7 | 97.5 | 98.7 | 97.4 |
Collected over Treatment-emergent Adverse Events (TEAEs) are reported. TEAEs are defined as adverse events with onset on or after the date of first intake of double-blind study treatment up to end of treatment plus 6 months (i.e., maximum of 18 months: Treatment Period 1 + Treatment Period 2 + 6-month safety follow-up period). Subjects who received cenerimod 4 mg and completed Treatment Period 1 were re-randomized to cenerimod 2 mg or placebo in Treatment Period 2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cenerimod 0.5 mg (Treatment Period 1 & 2) | 0/84 (0%) | 4/84 (4.8%) | 37/84 (44%) |
| Cenerimod 1 mg (Treatment Period 1 & 2) | 2/85 (2.4%) | 12/85 (14.1%) | 54/85 (63.5%) |
| Cenerimod 2 mg (Treatment Period 1 & 2) | 0/87 (0%) | 4/87 (4.6%) | 53/87 (60.9%) |
| Cenerimod 4 mg (Treatment Period 1) & Cenerimod 2 mg (Ex-4 mg; Treatment Period 2) | 0/35 (0%) | 1/35 (2.9%) | 23/35 (65.7%) |
| Cenerimod 4 mg (Treatment Period 1) & Placebo (Ex-4 mg; Treatment Period 2) | 0/35 (0%) | 0/35 (0%) | 20/35 (57.1%) |
| Cenerimod 4 mg (Treatment Period 1) & Not Re-randomized (Ex-4 mg; Treatment Period 2) | 0/14 (0%) | 2/14 (14.3%) | 13/14 (92.9%) |
| Placebo (Treatment Period 1 & 2) | 0/86 (0%) | 6/86 (7%) | 39/86 (45.3%) |
| Event | Cenerimod 0.5 mg (Treatment Period 1 & 2) | Cenerimod 1 mg (Treatment Period 1 & 2) | Cenerimod 2 mg (Treatment Period 1 & 2) | Cenerimod 4 mg (Treatment Period 1) & Cenerimod 2 mg (Ex-4 mg; Treatment Period 2) | Cenerimod 4 mg (Treatment Period 1) & Placebo (Ex-4 mg; Treatment Period 2) | Cenerimod 4 mg (Treatment Period 1) & Not Re-randomized (Ex-4 mg; Treatment Period 2) | Placebo (Treatment Period 1 & 2) |
|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/84 | 0/85 | 0/87 | 0/35 | 0/35 | 1/14 | 0/86 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/84 | 2/85 | 0/87 | 0/35 | 0/35 | 1/14 | 1/86 |
| Ovarian cystReproductive system and breast disorders | 0/84 | 0/85 | 0/87 | 0/35 | 0/35 | 1/14 | 0/86 |
| Hypertensive emergencyVascular disorders | 0/84 | 0/85 | 0/87 | 1/35 | 0/35 | 0/14 | 0/86 |
| Acute coronary syndromeCardiac disorders | 0/84 | 2/85 | 0/87 | 0/35 | 0/35 | 0/14 | 0/86 |
| COVID-19Infections and infestations | 0/84 | 2/85 | 0/87 | 0/35 | 0/35 | 0/14 | 0/86 |
| COVID-19 pneumoniaInfections and infestations | 1/84 | 2/85 | 0/87 | 0/35 | 0/35 | 0/14 | 1/86 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/84 | 1/85 | 0/87 | 0/35 | 0/35 | 0/14 | 0/86 |
| PneumoniaInfections and infestations | 1/84 | 1/85 | 0/87 | 0/35 | 0/35 | 0/14 | 0/86 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/84 | 0/85 | 0/87 | 0/35 | 0/35 | 0/14 | 0/86 |
| Event | Cenerimod 0.5 mg (Treatment Period 1 & 2) | Cenerimod 1 mg (Treatment Period 1 & 2) | Cenerimod 2 mg (Treatment Period 1 & 2) | Cenerimod 4 mg (Treatment Period 1) & Cenerimod 2 mg (Ex-4 mg; Treatment Period 2) | Cenerimod 4 mg (Treatment Period 1) & Placebo (Ex-4 mg; Treatment Period 2) | Cenerimod 4 mg (Treatment Period 1) & Not Re-randomized (Ex-4 mg; Treatment Period 2) | Placebo (Treatment Period 1 & 2) |
|---|---|---|---|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 4/84 | 10/85 | 12/87 | 7/35 | 4/35 | 5/14 | 1/86 |
| HeadacheNervous system disorders | 11/84 | 12/85 | 8/87 | 8/35 | 2/35 | 1/14 | 4/86 |
| HypertensionVascular disorders | 2/84 | 8/85 | 3/87 | 8/35 | 0/35 | 0/14 | 2/86 |
| COVID-19Infections and infestations | 8/84 | 8/85 | 10/87 | 1/35 | 2/35 | 2/14 | 11/86 |
| Lymphocyte count decreasedInvestigations | 0/84 | 0/85 | 5/87 | 0/35 | 1/35 | 2/14 | 0/86 |
| Upper respiratory tract infectionInfections and infestations | 7/84 | 4/85 | 5/87 | 4/35 | 2/35 | 1/14 | 1/86 |
| Urinary tract infectionInfections and infestations | 2/84 | 2/85 | 2/87 | 4/35 | 0/35 | 1/14 | 9/86 |
| Dry eyeEye disorders | 3/84 | 2/85 | 9/87 | 0/35 | 2/35 | 0/14 | 3/86 |
| DiarrhoeaGastrointestinal disorders | 4/84 | 4/85 | 3/87 | 3/35 | 0/35 | 0/14 | 3/86 |
| NasopharyngitisInfections and infestations | 5/84 | 0/85 | 6/87 | 3/35 | 1/35 | 1/14 | 5/86 |
| Age, Continuous(years) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 42.8 ± 12.41 | 40.0 ± 12.77 | 42.2 ± 12.06 | 42.1 ± 10.44 | 41.0 ± 11.94 | 41.6 ± 11.94 |
| Age, Customized(years) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Between 18 and 45 years | 49 | 54 | 49 | 50 | 57 | 259 |
| Between 45 and 64 years | 31 | 29 | 36 | 33 | 27 | 156 |
| Between 64 and 75 years | 5 | 2 | 1 | 2 | 2 | 12 |
| Sex: Female, Male(Participants) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 79 | 83 | 80 | 82 | 82 | 406 |
| Male | 6 | 2 | 6 | 3 | 4 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 17 | 18 | 19 | 19 | 89 |
| Not Hispanic or Latino | 69 | 68 | 68 | 65 | 66 | 336 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 3 | 6 | 1 | 3 | 18 |
| Asian | 5 | 9 | 7 | 6 | 6 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 3 | 6 | 8 | 10 | 6 | 33 |
| White | 72 | 67 | 65 | 65 | 68 | 337 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 3 | 2 | 5 |
| Region of Enrollment(participants) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Bulgaria | 5 | 2 | 1 | 3 | 2 | 13 |
| Chile | 1 | 3 | 2 | 5 | 7 | 18 |
| Czechia | 2 | 2 | 2 | 0 | 1 | 7 |
| France | 0 | 0 | 0 | 1 | 0 | 1 |
| Georgia | 5 | 3 | 1 | 4 | 2 | 15 |
| Greece | 0 | 0 | 1 | 0 | 0 | 1 |
| Israel | 0 | 1 | 1 | 0 | 0 | 2 |
| Italy | 1 | 1 | 0 | 1 | 1 | 4 |
| Mexico | 10 | 6 | 10 | 6 | 7 | 39 |
| Philippines | 4 | 7 | 6 | 5 | 5 | 27 |
| Poland | 6 | 2 | 3 | 3 | 7 | 21 |
| Romania | 1 | 0 | 0 | 1 | 0 | 2 |
| Russia | 2 | 8 | 7 | 5 | 2 | 24 |
| Spain | 1 | 2 | 0 | 0 | 4 | 7 |
| Taiwan | 0 | 0 | 1 | 1 | 0 | 2 |
| Thailand | 0 | 2 | 0 | 0 | 0 | 2 |
| Turkey | 0 | 0 | 1 | 0 | 0 | 1 |
| Ukraine | 36 | 29 | 29 | 27 | 29 | 150 |
| United Kingdom | 0 | 0 | 0 | 2 | 1 | 3 |
| United States | 11 | 17 | 21 | 21 | 18 | 88 |
| Body Mass Index(kilograms/square meter) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 25.67 ± 5.67 | 25.55 ± 5.95 | 26.16 ± 6.6 | 26.82 ± 7.15 | 26.49 ± 6.24 | 26.14 ± 6.33 |
| modified SLEDAI at baseline(units on a scale) | Cenerimod 0.5 mg | Cenerimod 1 mg | Cenerimod 2 mg | Cenerimod 4 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 9.8 ± 2.69 | 10.1 ± 3.71 | 9.5 ± 2.88 | 10.0 ± 2.50 | 10.2 ± 3.05 | 9.9 ± 2.99 |
Showing the first 100 of 148 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Aug 2021, 32 months.
Results were first posted in Sep 2023, 2 years after primary completion. A results delay was requested in Jul 2022.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 32 months is close to that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenerimod
Lupus Erythematosus, Systemic →